CADL241220P3000
- 0.40
- +0.05+14.29%
Candel Therapeutics Newsroom
H.C. Wainwright Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $11
HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $11 Price Target
Candel Therapeutics Analyst Ratings
Promising Potential of Candel Therapeutics' CAN-2409 Drives Buy Rating
HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $11 Price Target
Candel Therapeutics Analyst Ratings
Candel Therapeutics' Promising Clinical Progress and Financial Stability: A Buy Recommendation
Promising Potential of CAN-2409 Elevates Candel Therapeutics to a Buy Rating: A Detailed Analysis
H.C. Wainwright Sticks to Their Buy Rating for Candel Therapeutics (CADL)
Candel Therapeutics (CADL) Receives a Buy From H.C. Wainwright
HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $11 Price Target
BMO Capital Maintains Outperform on Candel Therapeutics, Lowers Price Target to $3
Credit Suisse Maintains Outperform on Candel Therapeutics, Lowers Price Target to $7
Credit Suisse Trims Candel Therapeutics' Price Target to $7 From $8, Updates Model to Reflect Q4 Actuals; Keeps Outperform Rating
UBS Adjusts Candel Therapeutics Price Target to $8 From $11, Maintains Buy Rating
H.C. Wainwright Keeps Their Buy Rating on Candel Therapeutics (CADL)
Credit Suisse Lowers Candel Therapeutics' Price Target to $8 From $10, Keeps Outperform Rating
BMO Capital Reaffirms Their Buy Rating on Candel Therapeutics (CADL)
Candel Therapeutics Analyst Ratings
Credit Suisse Maintains Outperform on Candel Therapeutics, Lowers Price Target to $8